|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,923.00 GBX | -2.51% |
|
+0.08% | +5.40% |
| Jun. 18 | Moderna Secures Favorable FDA Panel Recommendation for mRNA Flu Vaccine |  |
| Jun. 18 | The Gulf Gives, the Fed Takes | |
| Market Cap | 76.77B 101B 88.41B 81.55B 143B 9,562B 144B 972B 374B 4,707B 380B 372B 16,356B | P/E 2026 * |
12.3x | P/E 2027 * | 11.4x |
|---|---|---|---|---|---|
| Enterprise Value | 91.02B 120B 105B 96.68B 170B 11,337B 171B 1,152B 443B 5,581B 451B 441B 19,393B | EV / Sales 2026 * |
2.69x | EV / Sales 2027 * | 2.48x |
| Free-Float |
92.29% | Yield 2026 * |
3.64% | Yield 2027 * | 3.81% |
Last Transcript: GSK plc
| Jun. 15 | GSK slips despite positive analysis from UBS | |
| Jun. 15 | GSK : UBS remains Neutral | ZD |
| Jun. 10 | Intron Health Upgrades GSK to Hold Rating, Lifts PT | MT |
| Jun. 10 | GSK : Deutsche Bank reiterates its Neutral rating | ZD |
| Jun. 10 | GSK : UBS sticks Neutral | ZD |
| 1 day | -2.51% | ||
| 1 week | +0.08% | ||
| Current month | +2.21% | ||
| 1 month | +3.25% | ||
| 3 months | -4.47% | ||
| 6 months | +4.88% | ||
| Current year | +5.40% |
| 1 week | 1,906 |  | 2,011 |
| 1 month | 1,690 | | 2,191 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,288.6 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
| Chief Tech/Sci/R&D Officer | - | 2021-11-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 68 | 2019-08-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| Jun. 07 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| May. 21 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| May. 14 | Buy | Executive/Senior Manager | 82 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.51% | +0.08% | +29.93% | +40.92% | 105B | |
| -1.21% | -3.33% | +38.84% | +145.38% | 992B | |
| -2.48% | -4.23% | +49.88% | +39.07% | 564B | |
| -2.14% | -3.76% | +16.72% | +56.15% | 391B | |
| -1.18% | +0.68% | +24.66% | +16.53% | 330B | |
| -2.36% | -2.30% | +23.37% | +11.59% | 280B | |
| -2.45% | -0.84% | +23.51% | +30.06% | 279B | |
| -1.91% | -1.06% | -42.60% | -49.25% | 196B | |
| -1.19% | -0.04% | +16.39% | +47.00% | 184B | |
| -1.35% | +1.88% | +14.59% | +56.94% | 156B | |
| Average | -1.13% | +0.64% | +19.53% | +39.44% | 347.67B | |
| Weighted average by Cap. | -0.62% | -0.40% | +27.18% | +62.53% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.78B 44.61B 38.91B 35.89B 63.04B 4,208B 63.57B 428B 165B 2,072B 167B 164B 7,198B | 35.48B 46.85B 40.86B 37.69B 66.2B 4,419B 66.76B 449B 173B 2,175B 176B 172B 7,559B |
| Net income | 6.27B 8.27B 7.22B 6.66B 11.69B 781B 11.79B 79.33B 30.51B 384B 31.03B 30.39B 1,335B | 6.67B 8.81B 7.68B 7.08B 12.44B 831B 12.55B 84.43B 32.48B 409B 33.03B 32.34B 1,421B |
| Net Debt | 14.25B 18.82B 16.41B 15.14B 26.59B 1,775B 26.82B 180B 69.4B 874B 70.58B 69.12B 3,037B | 11.19B 14.78B 12.89B 11.89B 20.88B 1,394B 21.06B 142B 54.49B 686B 55.41B 54.26B 2,384B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-18 | 1,923.00 p | -2.51% | 7,565,889 |
| 26-06-17 | 1,972.50 p | +1.15% | 4,713,671 |
| 26-06-16 | 1,950.00 p | -0.41% | 6,759,886 |
| 26-06-15 | 1,958.00 p | -1.31% | 7,053,702 |
| 26-06-12 | 1,984.00 p | +1.10% | 5,539,234 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
